Current Edition

clinical

Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes

Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began recruiting patients into its multicenter …

Continue Reading →